Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

RBC Capital lowered its price target on Vertex Pharmaceuticals (NASDAQ: VRTX) to $420 from $423 on Monday, while maintaining a Sector Perform rating on the stock.The biotech giant, currently ...

The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic fibrosis treatment, Alyftrek. RBC Capital remains ...

Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Oral presentation on outcomes following ...

During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater ...

According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11.

ALYFTREK and TRIKAFTA are not recommended in patients with moderate hepatic impairment and should only be considered when there is a clear medical need and benefit outweighs risk.

Erste Group downgraded Vertex’s stock from Buy to Hold, citing concerns over high inventory and receivables ratios, despite the potential sales boost from the cystic fibrosis treatment ALYFTREK.

ALYFTREK. There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions.

During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore ...